Abstract
Laypersons, researchers and clinicians alike speak of the biotechnology revolution with excitement. Media coverage of new breakthroughs in medicine often have the public and the investment community on the edge of their seats, eager for the next blockbuster drug to cure everything from high cholesterol levels to cancer. In this perspective, we examine some of the more popularized and influential new technologies in drug discovery and assess their relative impact on the actual attainment of new therapeutics.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Merrifield, R. B. Solid-phase syntheses (Nobel lecture). Angew. Chem. 97, 801–812 (1985).
Elmblad, A. et al. Synthesis of mixed oligodeoxyribonucleotides following the solid phase method. Nucleic. Acids Res. 10, 3291–3301 (1982).
Bunin, B. A. & Ellman, J. A. A general and expedient method for the solid-phase synthesis of 1,4-benzodiazepine derivatives. J. Am. Chem. Soc. 114, 10997–10998 (1992).
Day, K. Testing a combination punch against disease. The Washington Post (Washington) (April 14, 1996).
Dolle, R. E. Comprehensive survey of combinatorial library synthesis: 2000. J. Comb. Chem. 3, 477–517 (2001).
Arya, P. et al. Toward high-throughput synthesis of complex natural product-like compounds in the genomics and proteomics age. Chem. Biol. 9, 145–156 (2002).
Sears, P. & Wong, C. -H. Toward automated synthesis of oligosaccharides and glycoproteins. Science 291, 2344–2350 (2001).
Wess, G. How to escape the bottleneck of medicinal chemistry. Drug Discov. Today 7, 533–535 (2002).
Auld, D. S. et al. Targeting signal transduction with large scale combinatorial collections. Drug Discov. Today 7, 1206–1213 (2002).
Hughes, D. Therapeutic antibodies make a comeback. Drug Discov. Today 3, 439–442 (1998).
Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495–497 (1975).
To, A. et al. Monoclonal antibodies: present and future. Credit Suisse First Boston Corporation (2000).
Schmeck, Jr, H. M. Gene studies emerging as key engine of science. The New York Times (September 6, 1988).
Debouck, C. & Metcalf, C. The impact of genomics on drug discovery. Annu. Rev. Pharmacol. Toxicol. 40, 193–208 (2000).
Zambrowicz, B. P. & Sands, A. T. Knockouts model the 100 best-selling drugs — will they model the next 100? Nature Rev. Drug. Discov. 2, 38–51 (2003).
Schmitt, C. A. & Lowe, S. W. Apoptosis and chemoresistance in transgenic animal models. J. Mol. Med. 80, 137–146 (2002).
De Angelis, F. G. et al. Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Δ 48–50 DMD cells. Proc. Natl Acad. Sci. USA 99, 9456–9461 (2002).
Specter, M. Computer is drug design's new mortar and pestle. Washington Post (December 17, 1988).
Whittaker, M. et al. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev. 99, 2735–2776 (1999).
Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44, 235–249 (2000).
Bemis, G. W. & Murcko, M. A. Properties of known drugs. 1. Molecular frameworks. J. Med. Chem. 39, 2887–2893, (1996).
Golub, T. R. et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531–537 (1999).
Scherf, U. et al. A gene expression database for the molecular pharmacology of cancer. Nature Genet. 24, 236–244 (2000).
Kodadek, T. Protein microarrays: prospects and problems. Chem. Biol. 8, 105–115 (2001).
Gerhold, D. L. et al. Better therapeutics through microarrays. Nature Genet. 32, 547–551 (2002).
Hodgson, J. ADMET — turning chemicals into drugs. Nature Biotechnol. 19, 722–726 (2001).
Ekins, S. & Rose, J. In silico ADME/Tox: the state of the art. J. Mol. Graph. Model 20, 305–309 (2002).
Schmitt, C. A. & Lowe, S. W. Apoptosis and chemoresistance in transgenic animal models. J. Mol. Med. 80, 137–146 (2002).
Zhang, J. et al. Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR. Science 298, 422–424 (2002).
Tarbit, M. H. & Berman, J. High-throughput approaches for evaluating absorption, distribution, metabolism and excretion properties of lead compounds. Curr. Opin. Chem. Biol. 2, 411–416 (1998).
Lipinski, C. A. et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3–25 (1997).
Beresford, A. P. et al. The emerging importance of predictive ADME simulation in drug discovery. Drug Discov. Today 7, 109–116 (2002).
Craigie, R. HIV integrase, a brief overview from chemistry to therapeutics. J. Biol. Chem. 276, 23213–23216 (2001).
Klapholz, M. Emerging therapies in heart failure. Cardiol. Spec. Ed. 7, 71–74 (2001).
Michels, D. A. et al. Fully automated two-dimensional capillary electrophoresis for high sensitivity protein analysis. Mol. Cell. Proteomics 1, 69–74 (2002).
Perkel, J. M. Tissue microarrays: advancing clinical genomics. The Scientist 21, 39 (2002).
Cornish, V. & Tao, H. Y. Milestones in directed enzyme evolution. Curr. Opin. Chem. Biol. 6, 858–864 (2002).
James, W. Nucleic acid and polypeptide aptamers: a powerful approach to ligand discovery. Curr. Opin. Pharmacol. 1, 540–546 (2001).
Acknowledgements
The authors wish to acknowledge helpful discussions with the associate consultants and advisors of AGW BioStrategy.
Author information
Authors and Affiliations
Corresponding author
Related links
Related links
DATABASES
Cancer.gov
LocusLink
Online Mendelian Inheritance in Man
FURTHER INFORMATION
Rights and permissions
About this article
Cite this article
Gershell, L., Atkins, J. A brief history of novel drug discovery technologies. Nat Rev Drug Discov 2, 321–327 (2003). https://doi.org/10.1038/nrd1064
Issue Date:
DOI: https://doi.org/10.1038/nrd1064
This article is cited by
-
Synthesis, Characterisation and In Vitro Permeation, Dissolution and Cytotoxic Evaluation of Ruthenium(II)-Liganded Sulpiride and Amino Alcohol
Scientific Reports (2019)
-
Dual-Targeting Pro-apoptotic Peptide for Programmed Cancer Cell Death via Specific Mitochondria Damage
Scientific Reports (2013)
-
“Artificial micro organs”—a microfluidic device for dielectrophoretic assembly of liver sinusoids
Biomedical Microdevices (2011)
-
Subcellular targeting strategies for drug design and delivery
Nature Reviews Drug Discovery (2010)
-
Fragment-based QSAR: perspectives in drug design
Molecular Diversity (2009)
